FDA approves Teva’s expanded indication for Uzedy for bipolar I disorder
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies
New study presents a human-relevant stress model for assessing potential therapeutics
Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
Investment to expand manufacturing and global medicine supply capacity
Trastuzumab Deruxtecan 100mg/5mL vial lyophilized powder for concentrate for solution for infusion is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors
India currently hosts more than 10,075 biotech startups
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
BIL also holds an option to increase its equity stake by an additional 15%
Subscribe To Our Newsletter & Stay Updated